Type 2 diabetes

Independent Pharmacy Cooperative (IPC) Secures Exclusive Distribution Rights to Independent Retail Pharmacies for BRENZAVVY® (bexagliflozin) with TheracosBio Partnership

Retrieved on: 
Thursday, February 1, 2024

SUN PRAIRIE, Wis., Feb. 1, 2024 /PRNewswire/ -- Independent Pharmacy Cooperative (IPC), the leading group purchasing organization owned by independent pharmacies nationwide, proudly announces an exclusive distribution partnership with TheracosBio to make BRENZAVVY® (bexagliflozin) accessible to its 6,000 member pharmacies.

Key Points: 
  • SUN PRAIRIE, Wis., Feb. 1, 2024 /PRNewswire/ -- Independent Pharmacy Cooperative (IPC), the leading group purchasing organization owned by independent pharmacies nationwide, proudly announces an exclusive distribution partnership with TheracosBio to make BRENZAVVY® (bexagliflozin) accessible to its 6,000 member pharmacies.
  • IPC, renowned for its commitment to supporting independent pharmacies, is set to be the first pharmaceutical wholesaler in the United States to carry and distribute BRENZAVVY.
  • BRENZAVVY, an FDA-approved oral sodium-glucose cotransporter 2 (SGLT2) inhibitor, presents a groundbreaking approach to diabetes care.
  • IPC members and customers will benefit from this exclusive arrangement, reinforcing IPC's commitment to expanding the range of cost-effective, clinically meaningful products available to independent pharmacies.

JDRF Awards $9 Million US for Phase 3 Type 1 Diabetes Kidney Disease Clinical Trial, Joins The Kidney Foundation of Canada in Driving Research to Treat Kidney Disease

Retrieved on: 
Monday, January 22, 2024

Kidney disease remains a life-threatening complication for those living with diabetes.

Key Points: 
  • Kidney disease remains a life-threatening complication for those living with diabetes.
  • Almost half of kidney failure cases are caused by diabetes, and an estimated one out of three people with T1D develop significant kidney disease.
  • SUGARNSALT is one of the largest T1D focused kidney disease studies in the world, and it is the only phase 3 clinical trial targeting major kidney disease outcomes.
  • "The Kidney Foundation of Canada is proud to be one of the founding partners on this significant investment to support innovative strategies to treat diabetic kidney disease.

Diabetes Canada awards over $6 million in funding to new research projects

Retrieved on: 
Monday, January 22, 2024

Each research project receives a $100,000 grant annually for three years for a total of $6.2 million in funds committed by Diabetes Canada for the research community.

Key Points: 
  • Each research project receives a $100,000 grant annually for three years for a total of $6.2 million in funds committed by Diabetes Canada for the research community.
  • “To achieve our vision of a world free of the effects of diabetes, Diabetes Canada knows that it needs to harness the transformative and combined power of technological, medical, and scientific research,” says Laura Syron, President and CEO of Diabetes Canada.
  • The winning research projects for this year’s Diabetes Canada’s End Diabetes Awards were rigorously evaluated by scientists with expertise in diabetes research, with input from people with lived experience, and Diabetes Canada’s National Research Council.
  • For almost 50 years, Diabetes Canada has proudly supported outstanding diabetes research in Canada, administering more than $160 million in research grants, awards and partnerships to scientists and clinicians who have dedicated their careers to the fight against diabetes.

Biodexa CEO Issues Shareholder Letter Highlighting Progress in 2023 and Expected Milestones in 2024

Retrieved on: 
Monday, January 22, 2024

In December 2023, we completed an in-licensing of a new, potentially disease modifying, orally delivered clinical stage molecule for Type I diabetes, an unmet medical disease.

Key Points: 
  • In December 2023, we completed an in-licensing of a new, potentially disease modifying, orally delivered clinical stage molecule for Type I diabetes, an unmet medical disease.
  • Tolimidone is an activator of lyn kinase which has been shown to play a significant role in cell proliferation, differentiation, apoptosis, migration and metabolism.
  • We expect to report data from the in vivo LMD efficacy model by the end of the first quarter of 2024.
  • Certain statements in this shareholder letter may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States.

Know Labs to Exhibit at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Retrieved on: 
Tuesday, January 23, 2024

Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the company will be exhibiting at the International Fair of New Technologies in Diabetes at the 17 th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy on March 6-9, 2024.

Key Points: 
  • Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced the company will be exhibiting at the International Fair of New Technologies in Diabetes at the 17 th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in Florence, Italy on March 6-9, 2024.
  • These results will be presented by Dr. Virend K. Somers of the Mayo Clinic, who serves as an author and co-investigator on Know Labs’ current clinical research protocol.
  • The protocol assesses the accuracy of the Know Labs radiofrequency (RF) sensor for non-invasive blood glucose measurement in participants with prediabetes and Type 2 diabetes using venous blood as comparative reference.
  • During the conference Know Labs will sponsor an invitation-only luncheon hosted by Children With Diabetes (CWD) where key thought leaders in the diabetes management field will discuss non-invasive glucose monitoring innovation.

Better Therapeutics Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx is More Effective and Less Costly than Standard of Care Alone

Retrieved on: 
Wednesday, January 17, 2024

The study's authors conclude that, from a healthcare payer perspective, AspyreRx plus standard of care (SoC) was estimated to be both economically and clinically superior to SoC alone over the lifetime horizon.

Key Points: 
  • The study's authors conclude that, from a healthcare payer perspective, AspyreRx plus standard of care (SoC) was estimated to be both economically and clinically superior to SoC alone over the lifetime horizon.
  • This suggests that the use of AspyreRx can empower patients to better manage their diabetes with the potential for lifelong advantages.
  • This latest study modeled the cost-effectiveness of AspyreRx plus SoC versus SoC alone in T2D over a lifetime horizon.
  • "The publication of this data, demonstrating that adding AspyreRx to standard of care has the potential to be more effective and less costly than standard of care alone, exemplifies our vision to make societies healthier and meaningfully reduce healthcare costs.”

Non-Alcoholic Steatohepatitis Treatment Drug Market In Japan is Expected to Showcase Impressive Growth by 2032 | DelveInsight

Retrieved on: 
Wednesday, January 17, 2024

LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.

Key Points: 
  • LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.
  • According to DelveInsight's analysis, the market size for NASH reached USD 200 million in 2022 in Japan and is expected to grow with a significant CAGR by 2032.
  • DelveInsight's analysis reveals that the overall diagnosed prevalent population of NASH in Japan was reported as 2.5 million in 2022.
  • Among the forecasted emerging therapies, MGL-3196 (Resmetirom) is expected to capture the highest market in Japan by 2032.

Non-Alcoholic Steatohepatitis Treatment Drug Market In Japan is Expected to Showcase Impressive Growth by 2032 | DelveInsight

Retrieved on: 
Wednesday, January 17, 2024

LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.

Key Points: 
  • LAS VEGAS, Jan. 17, 2024 /PRNewswire/ -- DelveInsight's Non-Alcoholic Steatohepatitis Market Insights report includes a comprehensive understanding of current treatment practices, non-alcoholic steatohepatitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into Japan.
  • According to DelveInsight's analysis, the market size for NASH reached USD 200 million in 2022 in Japan and is expected to grow with a significant CAGR by 2032.
  • DelveInsight's analysis reveals that the overall diagnosed prevalent population of NASH in Japan was reported as 2.5 million in 2022.
  • Among the forecasted emerging therapies, MGL-3196 (Resmetirom) is expected to capture the highest market in Japan by 2032.

ClearNote Health Announces New Proprietary Approach for Predicting Immunotherapy Treatment Response in Non-Small Cell Lung Cancer Using Only Blood

Retrieved on: 
Tuesday, January 16, 2024

The article, “ Plasma Cell-Free DNA Hydroxymethylation Profiling Reveals Anti-PD-1 Treatment Response and Resistance Biology in Non-Small Cell Lung Cancer ,” was published in the online issue of The Journal for ImmunoTherapy of Cancer, the official journal of the Society for Immunotherapy of Cancer (SITC) .

Key Points: 
  • The article, “ Plasma Cell-Free DNA Hydroxymethylation Profiling Reveals Anti-PD-1 Treatment Response and Resistance Biology in Non-Small Cell Lung Cancer ,” was published in the online issue of The Journal for ImmunoTherapy of Cancer, the official journal of the Society for Immunotherapy of Cancer (SITC) .
  • The comparison of plasma-derived cfDNA 5-hmC profiles revealed differences that distinguish patients responding to therapy from those not responding before and throughout treatment.
  • This underscores the value of 5hmC analysis for the measurement of treatment response biomarkers without the need for an invasive and potentially deadly tissue biopsy.
  • A recently published study in Cancer Research, “ The 5-Hydroxymethylcytosine Landscape of Prostate Cancer ,” showed the utility of ClearNote Health’s platform in marking epigenetic activation in prostate cancer and identifying hallmarks of prostate cancer progression.

Ultra-processed foods: here's what the evidence actually says about them

Retrieved on: 
Tuesday, January 16, 2024

Ultra-processed foods, in short, are commercially manufactured food products that include ingredients you wouldn’t cook with at home.

Key Points: 
  • Ultra-processed foods, in short, are commercially manufactured food products that include ingredients you wouldn’t cook with at home.
  • Some of this processing makes foods more palatable, some increases shelf life and makes them more affordable – such as wholemeal supermarket bread, for example.
  • A fair number of ultra-processed foods will have some of these unfavourable nutritional profiles – but many don’t.

Myths scrutinised

  • Nor is there strong evidence that whether a food is ultra-processed or not is what determines how it may affect your health.
  • Many studies have shown that people whose diets are high in ultra-processed foods have poorer health compared to those whose diets contain fewer ultra-processed foods.
  • However, research suggests that it’s some specific types of ultra-processed foods foods that are linked to worse health in studies that examine this, rather than all ultra-processed foods.
  • The study looked at whether ultra-processed food consumption was associated with developing cancer.
  • We also know that people from poorer backgrounds or who have worse mental health often eat more ultra-processed food.
  • Perhaps in the future, convincing evidence might show that some specific types of food processing can cause severe health problems.
  • But until then, sensationalist messages and misleading claims about ultra-processed food are very real problems.


I receive research funding from the ESRC, NIHR and ERC. During 2014-2016, I was a named investigator on projects funded by Unilever and the American Beverage Association. I do not receive any funding, financial awards or fees from the food industry.